Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Phill Febbo, Henry Fuchs, Woodrow Myers, Bob Holland


Genomic Health announced that Phill Febbo has joined the firm as its new chief medical officer. Febbo is an experienced physician scientist who was previously a professor of medicine and urology at the University of California, San Francisco. He will report to Steve Shak, Genomic Health's executive VP of R&D.

Additionally, Henry Fuchs, executive VP and CMO of Biomarin, has joined Genomic Health's board of directors. He has previously held leadership roles at Onyx and Genentech.

Woodrow Myers, managing director of Myers Ventures, will step down from his seven-year tenure on Genomic Health's board. Myers will now be CEO of Corizon, a provider of correctional healthcare services.

Oxford Gene Technology has named Bob Holland to be its new chief medical officer, the company said this week. Holland helped to create and was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division. In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.